Background/Aim: We investigated whether measuring the excretion of each acute kidney
injury (AKI) biomarker after cisplatin (CDDP) administration is useful for predicting AKI and …

Purpose Acute kidney injury (AKI) is a common and serious adverse effect of cisplatin-based
chemotherapy. However, traditional markers of kidney function, such as serum creatinine …

Background Several biomarkers are becoming available for the early detection of acute
kidney injury (AKI), but few have been directly compared. Objective To compare urinary …

Introduction Cisplatin-associated acute kidney injury (AKI) is the major limitation to the use of
cisplatin-based chemotherapy regimens. Serum creatinine as a traditional marker did not …

Cisplatin is still a widely used anticancer drug characterized by significant nephrotoxicity.
Acute kidney injury (AKI), diagnosed based on the Kidney Disease: Improving Global …

Despite recent progress in the development of novel approaches to treat cancer, traditional
antineoplastic drugs, such as cisplatin, remain a mainstay of regimens targeting solid …

Objective: Cisplatin is a potent antineoplastic agent used and its major limiting side effect is
nephrotoxicity. The aims of the study are early detection of acute kidney injury (AKI) with …

Cisplatin-induced acute kidney injury (AKI) is a major concern among clinicians in
prescribing cisplatin-based chemotherapy. This study evaluated and compared the ability of …

The success of cisplatin‐containing regimens to treat solid tumors is limited, in part, by
nephrotoxicity. In rodents, several urinary proteins have emerged that are sensitive …

Cisplatin is associated with dose-limiting nephrotoxicity, and the timely detection of acute
kidney injury (AKI) can affect morbimortality. Therefore, this study aimed to investigate the …